Hydroxychloroquine denied as experimental or investigational by Humana?

Humana's specific coverage criteria for hydroxychloroquine are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Hydroxychloroquine as Experimental

An "experimental" or "investigational" denial for hydroxychloroquine is unusual for its established indications — the drug has FDA approval for specific rheumatologic and antimalarial uses and has decades of clinical use. This denial most commonly arises when hydroxychloroquine is prescribed for an off-label condition that Humana has not yet recognized in its coverage policy, or when claims were submitted with a diagnosis code that does not map to a covered indication. It can also arise if the clinical context was not documented — a reviewer seeing an unfamiliar indication with no supporting notes may default to an experimental classification.

## Your Right to Appeal

Federal law provides strong protections for this category:

• ACA §2719 / External Review: Independent external review is available after internal exhaustion, generally within approximately four months of the denial date. External reviewers use current clinical literature and are not bound by Humana's internal policy alone.
• ERISA §503: Humana must disclose the specific criteria that led to the experimental classification and allow a full-and-fair review.
• Expedited review: If the patient's condition is serious or rapidly progressing, request expedited internal and external review simultaneously.

## What to Gather

1. FDA-approval documentation — obtain the current FDA-approved prescribing label for hydroxychloroquine and confirm whether the patient's diagnosis falls within the approved indications. If it does, cite this directly in the appeal. 2. Off-label support package (if applicable) — if the use is off-label, the prescriber's letter must cite the specific professional-society guideline (e.g., applicable ACR, EULAR, or AAD guidance) recognizing this use as accepted medical practice. 3. Prescriber medical-necessity letter — explaining the evidence basis for the prescription, the patient's diagnosis, prior treatments and outcomes, and why hydroxychloroquine is the appropriate choice. 4. Diagnosis documentation — chart notes, specialist letters, and diagnostic workup confirming the underlying condition. 5. Treatment history — dates and outcomes of prior therapies.

## Criteria-Mapping Approach

Obtain Humana's coverage policy for hydroxychloroquine and identify the specific experimental/investigational criteria that were applied. For each criterion, provide a direct answer: if the FDA label covers the indication, say so; if guidelines recognize the use, cite the organization; if prior treatments failed, document them with dates.

## Next Steps

File the internal appeal leading with the regulatory status argument. External review is particularly powerful for experimental denials because independent clinical reviewers assess whether the use reflects accepted medical practice — and for hydroxychloroquine's established indications, that standard is well met.